Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHINOOK THERAPEUTICS, INC.KDNY · Entity 110632 | Chief Medical Officer | February 10, 2022 | February 14, 2022 |
| CalciMedica, Inc.CALC · Entity 7804 | Director | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHINOOK THERAPEUTICS, INC.
Report date February 10, 2022 · Filed February 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,891 |
Ending reported balance
After 2022-02-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-02-10 · Exercise / conversion · Acquired 5,668 · Balance 10,282 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2022-02-11 · Sale · Disposed 2,391 · Balance 7,891 F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.64 to $12.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| Restricted Stock Units (RSU)SEC Table II · derivative / convertible security · Expires 2024-02-10 | Direct | 11,337 |
Reported balance
After 2022-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-10 · Exercise / conversion · Disposed 5,668 · Balance 11,337 F4: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F5: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.64 to $12.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F5: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.
CalciMedica, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2036-09-30 | Direct | 20,000 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 20,000 · Balance 20,000 F1: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 21:27 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001823197-26-000002 · form4-10052026_091008.xml · derivative · entry 1 Glicklich Alan · CIK 0001823197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-09-30 F1 · derivative.exercise_date: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001823197-26-000001 · form4-08212026_100824.xml · derivative · entry 1 Glicklich Alan · CIK 0001823197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-08-18 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 16:22 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 937 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001823197-25-000003 · form4-10142025_041014.xml · derivative · entry 1 Glicklich Alan · CIK 0001823197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 937 Underlying: Common Stock · 937 shares Expires 2035-10-12 F1 · derivative.exercise_date: Beginning October 1, 2025, 1/3rd of the shares subject to the option shall vest in equal monthly installments. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 22:23 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-25-018303 · form4-06262025_100646.xml · derivative · entry 4 Glicklich Alan · CIK 0001823197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-06-23 F5 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 22:23 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-018303 · form4-06262025_100646.xml · derivative · entry 3 Glicklich Alan · CIK 0001823197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-04-22 F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. F4 · derivative.exercise_date: 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 22:23 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 4,166 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-018303 · form4-06262025_100646.xml · derivative · entry 2 Glicklich Alan · CIK 0001823197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,166 Underlying: Common Stock · 4,166 shares Expires 2035-04-22 F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 22:23 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-018303 · form4-06262025_100646.xml · derivative · entry 1 Glicklich Alan · CIK 0001823197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-04-22 F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. F2 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 00:51 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001415889-25-001595 · form4-01172025_120159.xml · derivative · entry 1 Glicklich Alan · CIK 0001823197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-14 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest in equal monthly installments over a three year period following the date of grant. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 19:56 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 2,391 | $12.74 | $30,463.97 |
DisclosureSEC source: 0001209191-22-009563 · doc4.xml · nonDerivative · entry 2 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,891 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.64 to $12.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 19:56 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 5,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009563 · doc4.xml · derivative · entry 3 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,337 Underlying: Common Stock · 5,668 shares Expires 2024-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F5 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 19:56 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 5,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-009563 · doc4.xml · nonDerivative · entry 1 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 18:46 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 7,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060111 · doc4.xml · derivative · entry 3 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,208 Underlying: Common Stock · 7,103 shares Expires 2030-10-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 18:46 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Tax withholdingCommon Stock | 2,489 | $12.37 | $30,785.45 |
DisclosureSEC source: 0001209191-21-060111 · doc4.xml · nonDerivative · entry 2 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,614 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 18:46 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 7,103 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-060111 · doc4.xml · nonDerivative · entry 1 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 18:40 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001209191-21-041646 · doc4.xml · derivative · entry 3 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,662 Underlying: Common Stock · 20,000 shares Expires 2030-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the total shares on April 20, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 18:40 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 20,000 | $16.35 | $326,968.00 |
DisclosureSEC source: 0001209191-21-041646 · doc4.xml · nonDerivative · entry 2 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.17 to $16.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 18:40 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 20,000 | $0.42 | $8,400.00 |
DisclosureSEC source: 0001209191-21-041646 · doc4.xml · nonDerivative · entry 1 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 18:11 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantRestricted Stock (RSU)(Common Stock) · Derivative | 17,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010386 · doc4.xml · derivative · entry 2 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,005 Underlying: Common Stock · 17,005 shares Expires 2024-02-10 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 18:11 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $15.14 | $0.00 |
DisclosureSEC source: 0001209191-21-010386 · doc4.xml · derivative · entry 1 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 10, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 21:15 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantRestricted Stock Units (RSU) (Common Stock) · Derivative | 21,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054253 · doc4.xml · derivative · entry 3 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,311 Underlying: Common Stock · 21,311 shares Expires 2030-10-05 F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F5 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 21:15 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 62,660 | $0.00 Strike: $14.77 | $0.00 |
DisclosureSEC source: 0001209191-20-054253 · doc4.xml · derivative · entry 2 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,660 Underlying: Common Stock · 62,660 shares Expires 2030-10-05 F3 · derivative.exercise_date: The stock option vests as to 25% of the total shares on October 6, 2021, and thereafter vests as to 1/36 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 05, 2020 Filed Oct 7, 2020 21:15 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 242,662 | Not disclosed Strike: $0.42 | Not disclosed |
DisclosureSEC source: 0001209191-20-054253 · doc4.xml · derivative · entry 1 Glicklich Alan · CIK 0001823197 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,662 Underlying: Common Stock · 242,662 shares Expires 2030-04-21 F2 · price: Received in connection with the merger of Private Chinook into the Issuer in exchange for a stock option to acquire 830,500 shares of Private Chinook common stock for $0.12 per share. F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on April 20, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.